Coccidioidomycosis historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Coccidioidomycosis Microchapters
Home
Patient Information
Overview
Historical Perspective
Pathophysiology
Causes Coccidioides immitis Coccidioides posadasii
Differentiating Coccidioidomycosis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Chest X Ray
CT
MRI
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Coccidioidomycosis historical perspective On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Coccidioidomycosis historical perspective All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Coccidioidomycosis historical perspective
CDC on Coccidioidomycosis historical perspective
Coccidioidomycosis historical perspective in the news
Blogs on Coccidioidomycosis historical perspective
Directions to Hospitals Treating Coccidioidomycosis
Risk calculators and risk factors for Coccidioidomycosis historical perspective

Biological Warfare

C. immitis was investigated by the United States during the 1950s and 1960s as a potential biological weapon. The Cash strain received the military symbol OC, and original hopes were for its use as an incapacitant. As medical epidemiology later made clear, OC would have lethal effects on several segments of the population, so it was later considered a lethal agent. It was never standardized, and beyond a few field trials, it was never weaponized. Most military work on OC was on vaccines by the mid-1960s.